Winkler U H
Center for Obstetrics and Gynecology, University Hospital Essen, Germany.
Am J Obstet Gynecol. 1998 Sep;179(3 Pt 2):S51-61. doi: 10.1053/ob.1998.v179.a92633.
In some studies third-generation oral contraceptives have been reported to be associated with a higher risk of venous thromboembolism than are second-generation oral contraceptives, whereas recent, more refined studies have not confirmed this. The reasons for the alleged differences are under discussion, and differential effects on hemostasis have been proposed. Eighteen studies comparing second- and third-generation oral contraceptives with respect to their effects on hemostasis were analyzed. Significant changes from baseline were reported for many variables with both second- and third-generation oral contraceptives without significant between-group differences. Also, in a combined analysis of nonsignificant changes, no consistent pattern of change emerged for any marker, with the exception of higher factor VII levels associated with third-generation oral contraceptives. However, factor VII is not related to venous thromboembolism risk. In addition, 1 cross-sectional study with an unvalidated assay reported a higher ratio of activated protein C sensitivity with third-generation oral contraceptives. Only 2 components of the hemostatic system (factor VII and activated protein C sensitivity ratio) emerged as potentially differentially affected by second- and third-generation oral contraceptives; the association with venous thromboembolism risk is questionable in the former case and unknown in the latter.
在一些研究中,据报道第三代口服避孕药与静脉血栓栓塞风险较高有关,相比第二代口服避孕药而言,而近期更为精细的研究并未证实这一点。关于所谓差异的原因正在讨论中,并且有人提出了对止血的不同影响。分析了18项比较第二代和第三代口服避孕药对止血作用的研究。第二代和第三代口服避孕药的许多变量均报告了与基线相比的显著变化,但组间无显著差异。此外,在对无显著变化的综合分析中,除了与第三代口服避孕药相关的较高的因子VII水平外,任何标志物均未出现一致的变化模式。然而,因子VII与静脉血栓栓塞风险无关。此外,1项采用未经验证的检测方法的横断面研究报告称,第三代口服避孕药的活化蛋白C敏感性比值较高。止血系统中只有2个成分(因子VII和活化蛋白C敏感性比值)可能受到第二代和第三代口服避孕药的不同影响;前者与静脉血栓栓塞风险的关联存在疑问,后者则未知。